Clinical Trial Update: Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated whether more frequent contact with patients improves early detection and management of adverse events during Vandetanib treatment for …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medullary Thyroid Cancer

Drugs mentioned

• Vandetanib (Caprelsa) (vandetanib)

Snippet

Sponsor: Sanofi | Conditions: Locally Advanced or Metastatic Medullary Thyroid Cancer, Medullary Thyroid Cancer | Phase 3 | Status: COMPLETED | Results posted: 2014-11-24